Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
Authors' conclusion
In this subpopulation with moderately active RA, the efficacy and safety of filgotinib were similar to those in the overall FINCH 1 population (patients with active moderate to severe RA).
Study context
- Population
- Patients with RA and inadequate response to MTX with moderate baseline DAS28-CRP (>3.2 to ≤5.1)24.2% of FINCH 1 (N = 1755)
- Participants
- 425 patients
- Comparison
- Filgotinib 200 mg or 100 mg once daily vs adalimumab 40 mg every 2 weeks vs placebo, all with MTX
- Primary endpoint
- ACR20 response
- Follow-up
- Week 12
Methodological detailspost hoc analysis, subgroup analysis
- Post hoc analysis
- Subgroup analysis
Primary result
As reported in the abstract
Further findings
DAS28-CRP <2.6, Clinical Disease Activity Index (CDAI) remission (≤2.8), low disease activity (LDA) (DAS28-CRP ≤3.2 or CDAI ≤10) and ACR20/50/70 responses · weeks 12 and 24
- Higher proportion with FIL200 and FIL100 vs placebo
DAS28-CRP LDA · week 24
- Achieved with either filgotinib dose
- ∼75%
Patient-reported outcomes
- Greater improvements with FIL200 and FIL100 than placebo
Efficacy through week 52
- Filgotinib efficacy maintained and comparable to adalimumab
Safety
Adverse events
- Frequency similar with filgotinib and adalimumab
Infections (most common adverse events (AEs))
- Incidence rates in active treatment groups
- 40-53%
Original publication
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate. Rheumatology (Oxford). Published 27 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →